|
COPYRIGHT 2003 Thomson Financial Inc.
In arguing against allowing Americans to buy less expensive prescription drugs from abroad, Food and Drug Administration head Mark McClellan, MD, has argued that the real answer to high U.S. drug prices is for other developed nations to step up and pay for their fair share of pharmaceutical research and development.
But at least one prominent health economist, Wharton School of Business's Patricia Danzon, thinks McClellan is wrong. Not about "reimportation," which Danzon opposes as much as McClellan does. Danzon, however, says the...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
